GlassScriptPhysician profile
Ali MD Khalid
NPI 1912586652
$1,622.20
in general payments reported to CMS, 2019-2025
23 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2024: $352 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $208.12 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.80 | 2022-2025 | Breztri |
| Novo Nordisk INC | $188.67 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $182.59 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $132.61 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.88 | 2024-2025 | Jardiance |
| Abbvie INC. | $81.45 | 2024-2025 | |
| Glaxosmithkline, LLC. | $68.76 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $66.99 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $62.59 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $53.10 | 2025 | |
| Exact Sciences Corporation | $41.80 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.88 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $23.20 | 2025 | Camzyos |
| Sumitomo Pharma America, INC. | $22.61 | 2025 | Gemtesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $21.32 | 2024 | Kristalose |
| Insightec,INC | $20.62 | 2025 | Exablate |
| Takeda Pharmaceuticals U.S.A., INC. | $20.23 | 2025 | Hyqvia |
| Tempus Ai, INC | $19.01 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $18.03 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.84 | 2024 | Xarelto |
| Xeris Pharmaceuticals, INC. | $17.82 | 2025 | Gvoke Hypopen |
| Seqirus USA INC | $14.28 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.